Article Text

Download PDFPDF
Randomised controlled trial
Treatment with the probiotic VSL#3 as an adjunctive therapy in relapsing mild-to-moderate ulcerative colitis significantly reduces ulcerative colitis disease activity
  1. Jean-François Turcotte1,
  2. Hien Q Huynh1
  1. 1Stollery Children's Hospital, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
  1. Correspondence to Hien Q Huynh
    Aberhart Centre Room 9219, 11402 University Avenue NW, Edmonton, AB T6G 2J3, Canada; hien.huynh{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science.


Ulcerative colitis (UC) is a chronic inflammatory disorder affecting the large bowel. Currently recognised therapies act in controlling the inflammation associated with this disease. However, the intestinal microbiome seems to play a major role in the pathogenesis of the disease. Therefore, the modulation of the gut flora using probiotics has been suggested as a way to maintain balance as well as integrity of the intestinal flora. However, the available evidence is limited in regard to the use of probiotics to induce remission as adjunctive therapy in mild-to-moderate UC – mostly as large, randomised, placebo-controlled trials have yet to be performed. The goal of this study was to assess whether adding VSL#3 to standard maintenance treatment of patients with relapsing mild-to-moderate UC would improve clinical symptoms and induce remission.


The authors conducted …

View Full Text


  • Competing interests None.